Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer.
about
The significance of tumor-associated immune response in molecular taxonomy, prognosis and therapy of colorectal cancer patientsSerrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapyPrediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer.Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial.Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stageThe consensus molecular subtypes of colorectal cancerAnalysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance.What We Know About Stage II and III Colon Cancer: It's Still Not Enough.Ezrin expression combined with MSI status in prognostication of stage II colorectal cancer.Invasion pattern and histologic features of tumor aggressiveness correlate with MMR protein expression, but are independent of activating KRAS and BRAF mutations in CRC.Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in melanoma patients.Prognostic value of the combination of microsatellite instability and mutation in colorectal cancerMutation Status and Immunohistochemical Correlation of , and in 260 Chinese Colorectal and Gastric Cancers
P2860
Q26738665-8CFACCF8-A248-4523-B628-56B734C962A7Q26751035-EF44D246-7EBE-4BB5-8875-D1E3727E768EQ33608167-AE50A2C5-8295-4492-A22D-19AD02FD3CE4Q33679614-85697CC9-C86C-4011-9771-90F0C2867214Q34038277-1AE31005-9A65-41C7-97D0-DB8E657F208EQ35625752-543F9F43-A4D2-4101-B9EA-6DC691650B96Q36258187-9940C936-384E-4DBB-8737-55E217D0F6BCQ36342900-AD8AFE63-977F-42A6-8D49-BA8FDBB00A68Q38383214-8DA407DE-E8E6-4CCB-A178-3D2D7C818F03Q38405130-B65D426E-2D71-49E1-A150-F111FA0A8B07Q38421451-8E8FBFBE-D5AF-4CC0-84D9-795C1E693859Q38847613-7E3A9DDE-E935-40F2-879F-DFB3EC5844E7Q38901400-E6160FE6-A15E-45D9-BF0C-D5BC97B147DFQ39306576-0BD22CC1-A29F-41DF-9D87-3131FCF39E1CQ42256619-DCAE59ED-8E71-4712-90D5-191FDB6AE686Q54345735-65DBD5DE-43DE-447B-9C82-6489FF96439AQ54375442-9AF34F73-A71E-4111-B39B-9D102F1A3EEDQ57491315-788187B5-15DB-41CB-B984-7BE266D8A66EQ58707595-B056B7FF-50BC-4DF3-A3C8-D81C725B7A69
P2860
Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Context-dependent interpretati ...... utations in colorectal cancer.
@ast
Context-dependent interpretati ...... utations in colorectal cancer.
@en
type
label
Context-dependent interpretati ...... utations in colorectal cancer.
@ast
Context-dependent interpretati ...... utations in colorectal cancer.
@en
prefLabel
Context-dependent interpretati ...... utations in colorectal cancer.
@ast
Context-dependent interpretati ...... utations in colorectal cancer.
@en
P2093
P2860
P356
P1433
P1476
Context-dependent interpretati ...... utations in colorectal cancer.
@en
P2093
Arnaud D Roth
Eva Budinska
Fred T Bosman
Mauro Delorenzi
Vlad Popovici
P2860
P2888
P356
10.1186/1471-2407-13-439
P407
P577
2013-09-27T00:00:00Z
P5875
P6179
1017780160